PA tag NZ-1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PA tag mAb (NZ-1; rat IgG2a) |
PAtag (GVAMPGAEDDVV;12 amino acid); trademark: No. 5671624; from AMED・PDIS project | Purification, IP, IHC, WB, FACS | PEP2014;
JCS2016 PS2019; AC2021 Sci2022; PSSJ; Wako |
○ |
in preparation
|
anti-PA14 tag mAb (NZ-1;rat IgG2a, lambda) |
PA14 tag (EGGVAMPGAEDDVV); from AMED・SentanBio | Purification, IP, IHC, WB, FACS |
PA14 tag system hGH-fusion Fab |
○ | in preparation |
anti-PA16 tag mAb (NZ-1;rat IgG2a, lambda) |
PA16 tag(GLEGGVAMPGAEDDVV); from AMED・SentanBio | Purification, IP, IHC, WB, FACS | C44Mab5; PMab202; PMab210; PMab213; PMab219; PMab233 | ○ | in preparation |
MAP tag PMab-1 | Character | Application | Ref | Gene cloning | Company |
anti-MAP tag mAb (PMab-1;rat IgG2a, kappa)--> PAtag |
MAPtag (GDGMVPPGIEDK;12 amino acids); trademark: No. 5988384; from AMED・KakushinBio; press release | Purification, IP, IHC, WB, FACS | MAB2016 BBREP2018 JB2020 |
○ |
AA; abcam; Nov; Merck; BioLegend in preparation |
anti-MAP16 tag mAb (PMab-1;rat IgG2a, kappa) |
MAP16 tag (PGTGDGMVPPGIEDKI;16 amino acids); from AMED・Tousa | Purification, IP, IHC, WB, FACS | PMab-235
PMab-44_goat |
○ | in preparation |
RAP tag PMab-2 | Character | Application | Ref | Gene cloning | Company |
anti-RAP tag mAb (PMab-2;mouse IgG1, kappa)--> PAtag |
RAP tag (DMVNPGLEDRIE; 12 amino acids); from AMED・KakushinBio | Purification, IP, IHC, WB, FACS | MAB2017 FPS2020 PP2021 |
○ |
AA;
abcam Merck; BioLegend |
anti-RAP14 tag mAb(double tag) (PMab-2; LpMab-7) |
RAP14 tag(DMVNPGLEDRIEDL; 14 amino acids); from AMED・Tousa | Purification, IP, IHC, WB, FACS | PMab44; PMab256; PDF; PMab253 | ○ | |
anti-RAP16 tag mAb (PMab-2;mouse IgG1, kappa) |
RAP16 (GPGDDMVNPGLEDRIE; 16 amino acids); from AMED・SentanBio | Purification, IP, IHC, WB, FACS | PMab-225_alpaca
PMab-225_epitope PMab-44_alpaca |
○ | |
RIEDL tag LpMab-7 | Character | Application | Ref | Gene cloning | Company |
anti-RIEDL tagmAb (LpMab-7;mouse IgG1, kappa)-->PAtag |
RIEDLtag (RIEDL; 5 amino acids): from AMED・SentanBio | Purification, IP, IHC, WB, FACS | RIEDL; PMab237 (1); PMab237 (2); C44-5; C44-46; E134; E51 | ○ | abcam |
MBP tag TMab-2 | Character | Application | Ref | Gene cloning | Company |
anti-MBP tag mAb (TMab-2;rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
○ | |
anti-MBP tag mAb (YM-2;rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
○ | BioLegend |
BAP tag PMab-44 | Character | Application | Ref | Gene cloning | Company |
anti-BAP tagmAb (PMab-44;mouse IgG1, kappa)--> PAtag |
BAP tag(EKTTLGVEDYTTTPAA; 16 amino acids); from AMED・BINDS・SentanBio | Purification, IP, IHC, WB, FACS | PMab247 PMab241 |
○ | Zenogen |
LP tag LpMab-17 | Character | Application | Ref | Gene cloning | Company |
anti-LP tag mAb (LpMab-17;mouse IgG1, kappa)-->PAtag |
LPタグ(NSVTGIRIEDLPTSES; 16 amino acids); from AMED・BINDS・SentanBio | Purification, IP, IHC, WB, FACS | PMab52 PMab231 |
○ |
BD Merck |
His tag HisMab-1 | Character | Application | Ref | Gene cloning | Company |
anti-His tag (HisMab-1;mouse IgG2b, kappa)-->PAtag | His tag (HHHH; 4 amino acids); from AMED・SentanBio | Purification, IP, IHC, WB, FACS |
C20Mab60 Rituximab C20Mab11 |
○ | |
anti-His tag; (HisMab-1-hG1;human IgG1, kappa) | His tag (HHHH; 4 amino acids); from AMED・SentanBio | Purification, IP, IHC, WB, FACS | ○ |
mouse CCR1 (CD191) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-mouse CCR1 mAb | in preparation |
FACS | |||
mouse CCR2 (CD192) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR2 mAb(C2Mab-6;rat IgG1, kappa) | specific for mouse CCR2; expressed in L1210; peptide immunization --> anti-human CCR2 |
FACS, WB, ICC |
C2Mab-6 epitope |
○ | in preparation |
mouse CCR3 (CD193) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR3 mAb(C3Mab-2;rat IgG2b, kappa) |
specific formouse CCR3; expressed in P388 or J774-1; established by CBIS method | FACS |
C3Mab-2 ICC |
○ | |
anti-mouse CCR3 mAb(C3Mab-3;rat IgG2a, kappa) | specifc mouse CCR3; expressed in P388 or J774-1; established by CBIS method。 | FACS |
C3Mab-3 epitope |
○ | |
anti-mouse CCR3 mAb(C3Mab-4;rat IgG2a, kappa) | specific mouse CCR3; expressed in P388 or J774-1; established by CBIS method | FACS | epitope | ○ | in preparation |
anti-mouse CCR3 mAb(C3Mab-6;rat IgG1, kappa) | specific mouse CCR3; expressed in P388 or J774-1; peptide immunization | FACS |
C3Mab-6 epitope |
○ | in preparation |
anti-mouse CCR3 mAb(C3Mab-7;rat IgG1, kappa) | specific mouse CCR3; expressed in P388 or J774-1; peptide immunization | FACS |
C3Mab-7 epitope-1 epitope-2 |
○ | in preparation |
mouse CCR4 (CD194) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR4 mAb(C4Mab-1;rat IgG1, kappa) | specific for mouse CCR4; expressed in P388 or J774-1; peptide immunization | FACS |
C4Mab-1 epitope |
○ | |
mouse CCR5 (CD195) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR5 mAb | in preparation |
FACS | |||
mouse CCR6 (CD196) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR6 mAb(C6Mab-9;rat IgG1, kappa) | specific for mouse CCR6; expressed in P388 or J774-1; peptide immunization
--> anti-human CCR6 |
FACS | ○ | in preparation | |
anti-mouse CCR6 mAb(C6Mab-13;rat IgG1, kappa) | specific for mouse CCR6; expressed in P388 or J774-1; peptide immunization | FACS |
C6Mab-13 epitope |
○ | |
mouse CCR7 (CD197) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR7 mAb | in preparation |
FACS | |||
mouse CCR8 (CD198) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR8 mAb(C8Mab-1; rat IgG2a, kappa) |
specific mouse CCR8; expressed in P388, J774-1; established by CBIS method | FACS, ICC | C8Mab-1 | ○ | |
anti-mouse CCR8 mAb(C8Mab-2; rat IgG2b, kappa) |
specific mouse CCR8; expressed in P388 or J774-1; established by CBIS method | FACS, ICC (anti-CCR8 mAb of Shionogi) |
C8Mab-2 ICC |
○ | |
anti-mouse CCR8 mAb(C8Mab-3; rat IgG1, kappa) |
specific mouse CCR8; expressed in P388 or J774-1; established by CBIS method | FACS, ICC | C8Mab-3 | ○ | |
mouse CCR8 (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR8 mAb (C8Mab-2-mG2a) | specific mouse CCR8; expressed in P388 or J774-1; established by CBIS method | FACS, ICC | ○ |
|
|
mouse CCR9 (CD199) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR9 mAb(C9Mab-24;rat IgG2a, kappa) | specific for mouse CCR9; expressed in P388 or J774-1; peptide immunization --> anti-human CCR9 |
FACS、WB |
C9Mab-24 epitope |
○ | |
mouse CCR10 | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR10 mAb | in preparation |
FACS | |||
mouse CCR11 | Character | Application | Ref | Gene cloning | Company |
anti-mouse CCR11 mAb | in preparation |
FACS | |||
mouse CXCR1 (CD181) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR1 mAb | in preparation |
FACS | |||
mouse CXCR2 (CD182) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR2 mAb | in preparation |
FACS | |||
mouse CXCR3 (CD183) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR3 mAb | in preparation |
FACS | |||
mouse CXCR4 (CD184) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR4 mAb | in preparation |
FACS | |||
mouse CXCR5 (CD185) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR5 mAb | in preparation |
FACS | |||
mouse CXCR6 (CD186) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR6 mAb(CX6Mab-1; rat IgG1, kappa) | specific for mouse CXCR6; expressed in P388 or J774-1; peptide immunization | FACS, WB |
CX6Mab-1 epitope-1 epitope-2 |
○ | in preparation |
anti-mouse CXCR6 mAb(CX6Mab-5; rat IgG1, kappa) | specific for mouse CXCR6; expressed in P388 or J774-1; peptide immunization | FACS, WB | ○ | in preparation | |
mouse CXCR7 (CD187) | Character | Application | Ref | Gene cloning | Company |
anti-mouse CXCR7 mAb | in preparation |
FACS | |||
mouse XCR1 | Character | Application | Ref | Gene cloning | Company |
anti-mXCR1 mAb | in preparation | FACS | |||
mouse CX3CR1 | Character | Application | Ref | Gene cloning | Company |
anti-mouse CX3CR1 mAb | in preparation |
FACS |
human CCR2 (CD192) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hCCR2 mAb (C2Mab-9;mouse IgG1, kappa) |
specific for human CCR2; expressed in U937 or NK cell; peptide immunization --> anti-mouse CCR2 |
FACS, ICC |
C2Mab-9 epitope |
○ | |
human CCR6 (CD196) | Character | Application | Ref | Gene cloning | Company |
anti-hCCR6 mAb (C6Mab-19;mouse IgG1, kappa) | specific for human CCR6; expressed in HepG2 or HuH-7; peptide immunization --> anti-mouse CCR6 |
FACS, IHC, ELISA |
MAB (submit) |
||
human CCR9 (CD199) | Character | Application | Ref | Gene cloning | Company |
anti-hCCR9 mAb (C9Mab-1;mouse IgG1, kappa) | specific for human CCR9; developmed by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) (SunRock) --> anti-mouse CCR9 | FACS |
C9Mab-1;
epitope ICC |
○ |
BD;
exbio Novus Thermo |
anti-hCCR9 mAb (C9Mab-6;mouse IgG1, kappa) | specific for human CCR9; established by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
anti-hCCR9 mAb (C9Mab-8;mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
anti-hCCR9 mAb (C9Mab-9;mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
anti-hCCR9 mAb (C9Mab-10;mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
anti-hCCR9 mAb (C9Mab-11;mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS、WB |
C9Mab-11 epitope |
○ | |
anti-hCCR9 mAb (C9Mab-12;mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
anti-hCCR9 mAb (C9Mab-13;mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
anti-hCCR9 mAb (C9Mab-14;mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
anti-hCCR9 mAb (C9Mab-16;mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
anti-hCCR9 mAb (C9Mab-17;mouse IgG2b, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
anti-hCCR9 mAb (C9Mab-18;mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
anti-hCCR9 mAb (C9Mab-19;mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
anti-hCCR9 mAb (C9Mab-21;mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
human XCR1 | Character | Application | Ref | Gene cloning | Company |
anti-hXCR1 mAb (X1Mab-4;mouse IgG1, kappa) | specific for human XCR1; established by peptide immunization | FACS | |||
anti-hXCR1 mAb (X1Mab-47;mouse IgM, kappa) | specific for human XCR1; established by CBIS (immunization of MDA-MB-157/PA-hXCR1) | FACS |
mouse EGFR | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb; EMab-300 (rat IgG1, kappa) | specific for mouse EGFR | FACS | EMab-300 | in preparation | |
anti-mouse/human EGFR mAb; EMab-88 (mouse IgG1, kappa) | specific for EGFR; EMab-88 was developed against human EGFR; crossreacts with mouse EGFR (domain-III) | FACS | data | ○ |
human EGFR domain-I | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb (EMab-23;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-I | FACS | ○ | ||
anti-EGFR mAb (EMab-78;mouse IgG2b, kappa) |
specific for EGFR; reacts with domain-I | FACS | ○ | ||
anti-EGFR mAb (EMab-129;mouse IgG1, lambda) |
specific for EGFR; reacts with domain-I | FACS | ○ | ||
human EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-19;mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | ○ | ||
anti-EGFR mAb (EMab-33;mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | ○ | ||
anti-EGFR mAb (EMab-57;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | ○ | ||
anti-EGFR mAb (EMab-76;mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | ○ | ||
human EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-134;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-134
epitope-1 epitope-2 |
○ |
abcam BD |
anti-EGFR mAb (EMab-51;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-51 epitope |
○ | |
anti-EGFR mAb (EMab-17;mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | EMab-17 metastasis |
○ | |
anti-EGFR mAb (EMab-1;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
anti-EGFR mAb (EMab-32;mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
anti-EGFR mAb (EMab-114;mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
anti-EGFR mAb (EMab-125;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | ○ | ||
anti-EGFR mAb (EMab-139;mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | ○ | ||
anti-EGFR mAb (EMab-151;mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
human EGFR domain-IV | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (EMab-95;mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | ○ | ||
anti-EGFR mAb (EMab-110;mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | ○ |
human EGFR (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb (134-mG2a;mouse IgG2a, kappa) |
mouse IgG2a version of EMab-134; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC/CDC, antitumor activities | 134-mG2a | ○ | |
anti-EGFR mAb (51-mG2a;mouse IgG2a, kappa) |
mouse IgG2a version of EMab-51specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | ○ | ||
anti-EGFR mAb (51-mG2a-f;mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-51; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | ○ | ||
anti-EGFR mAb (recEMab-17-f;mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-17; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | ○ |
dog EGFR | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EGFR mAb (134-mG2a-f;mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR OS; Fibro Mammary |
○ | |
anti-EGFR mAb (E134Bf;canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
○ |
bispecific | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | ○ | |
anti-EGFR-PDPN mAb (E134-NZ1scFv-mG2a-f) |
bispecific mAb for EGFR and PDPN | FACS, WB, IHC, ADCC, CDC, antitumor activities | ○ |
mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-300 ;rat IgG2b, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | data
in preparation |
ongoing | |
anti-HER2 mAb (H2Mab-303 ;rat IgG2a, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | ongoing | in preparation | |
anti-HER2 mAb (H2Mab-304 ;rat IgG1, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS, WB | data
in preparation |
ongoing | in preparation |
anti-HER2 mAb (H2Mab-307 ;rat IgG2a, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | ongoing | in preparation | |
anti-HER2 mAb (H2Mab-314 ;rat IgG1, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS, WB | ongoing |
mouse HER2 (CD340) mouse IgG2a | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-1301 ;rat IgG2a, lambda) |
Mab30; specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
anti-HER2 mAb (H2Mab-1316 ;rat IgG2a, kappa) |
Mab-31; specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
anti-HER2 mAb (H2Mab-1319 ;rat IgG2a, kappa) |
Mab-32; specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted |
mouse HER2 (CD340) mouse IgG2a | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-1301-mG2a ;mouse IgG2a, kappa) |
specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
anti-HER2 mAb (H2Mab-1316-mG2a ;mouse IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
anti-HER2 mAb (H2Mab-1319-mG2a ;mouse IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted |
mouse HER2 (CD340) humanized | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-1301-hG1 ;human IgG1, kappa) |
specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
anti-HER2 mAb (H2Mab-1316-hG1 ;human IgG1, kappa) |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
anti-HER2 mAb (H2Mab-1319-hG1 ;human IgG1, kappa) |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted |
HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-77;mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; (参考:TNBC) | FACS, WB, IHC | H2Mab-77 | ○ | BioLegnd |
anti-HER2 mAb (H2Mab-119;mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-119 PCT/JP2021/043538 |
○ | |
anti-HER2 mAb (H2Mab-139;mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-139 | ○ | abcam |
HER2 domain-III | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-19;mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-III | FACS, ADCC/CDC, antitumor activities | PC
CRC GBM |
○ | |
anti-HER2 mAb (H2Mab-181;mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; domain-III; epitope: p373ー392。 | FACS, WB, IHC | H2Mab-181 epitope |
○ | |
HER2 domain-IV | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H2Mab-41;mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
○ | |
anti-HER2 mAb (H2CasMab-1;mouse IgG1, kappa) |
specific for HER2; domain-IV | FACS, WB, IHC | ○ | restricted |
HER2 (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H2Mab-77-mG2a-f;mouse IgG2a) |
specific for HER2; crossreacts with dog HER2; (ref:TNBC) | FACS, WB, IHC | ○ | ||
anti-HER2 mAb (H2Mab-119-mG2a-f;mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | ○ | ||
anti-HER2 mAb (H2CasMab-1-mG2a-f;mouse IgG2a) |
specific for HER2; domain-IV | FACS, WB, IHC | ○ | restricted |
dog HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER2 mAb (H77Bf;canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
○ |
HER3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti HER3 mAb (H3Mab-17;mouse IgG2a, kappa) |
specific for HER3 | FACS, ADCC/CDC, antitumor activities | H3Mab-17 | ○ | exbio |
HER3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti HER3 mAb (H3Mab-1059;mouse IgG1,kappa) |
Mab1 for HER3 | FACS | restricted | ||
anti HER3 mAb (H3Mab-1170;mouse IgG1,kappa) |
Mab2 for HER3 | FACS | restricted |
HER4 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HER4 mAb (H4Mab-12~; mouse IgG) | specific for HER4 | FACS |
KLRG1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-KLRG1 mAb (KLMab-1;mouse IgG1, kappa) |
specific for human KLRG1 | FACS、ICC | KLMab-1 ICC |
○ |
PD-L1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L1 mAb (L1Mab-13;mouse IgG1, kappa) |
specific for human PD-L1 | FACS, WB, IHC (cell), IHC (tissue), ELISA | L1Mab-13 | ○ |
PD-L1 (to IgG1) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L1 mAb (13-mG2a-f;mouse IgG2a, kappa) |
specific for human PD-L1; core fucose-deficient IgG2a of L1Mab-13 | FACS, WB, IHC (cell), IHC (tissue), ELISA, ADCC/CDC, antitumor activities | 13-mG2a-f | ○ |
dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-dog PD-L1 mAb (L1Mab-347;mouse IgG1, kappa) |
specific for dog PD-L1 (extracellular domain) | FACS, IHC | ○ | ||
anti-dog PD-L1 mAb (L1Mab-348; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-349; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-350; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-351; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
anti-dog PD-L1 mAb (L1Mab-353; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
anti-dog PD-L1 mAb (L1Mab-355; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-356; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA |
PD-L2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PD-L2 mAb (L2Mab-1;mouse IgG2b, kappa) |
specific for PD-L2 | FACS, WB, IHC (cell) | ○ |
TIGIT | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TIGIT mAb (TgMab-2;mouse IgG1, kappa) |
specific for TIGIT | FACS、WB、ICC |
TgMab-2 ICC |
○ | BD |
CD19 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD19 mAb (C19Mab-1;mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | C19Mab-1 | ○ | |
anti-CD19 mAb (C19Mab-2;mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ○ | ||
anti-CD19 mAb (C19Mab-3;mouse IgG1, kappa) |
specific for CD19; CBIS method; ectodomain of CD19 immunization | IHC,WB | C19Mab-3 | ○ | |
anti-CD19 mAb (C19Mab-9G6; mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ○ | restricted | |
anti-CD19 mAb (C19Mab-10G3; mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ○ | restricted |
CD19 (for CAR-T) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD19 mAb (C19Mab-9G6-scFv;mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ○ | restricted | |
anti-CD19 mAb (C19Mab-10G3-scFv;mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ○ | restricted |
CD19 (humanized) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD19 mAb (humC19Mab-9G6-hG1; human IgG1) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ongoing | restricted | |
anti-CD19 mAb (humC19Mab-10G3-hG1; human IgG1) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ongoing | restricted |
CD19 (humanized; for CAR-T) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD19 mAb (humC19Mab-9G6-scFv; human IgG1) |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ongoing | restricted | |
anti-CD19 mAb (humC19Mab-10G3-scFv; human IgG1) |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ongoing | restricted |
CD20 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
抗CD20 mAb (C20Mab-11;mouse IgM, kappa) |
specific for CD20 | FACS, WB, IHC |
C20Mab-11 epitope |
ongoing | |
抗CD20 mAb (C20Mab-60;mouse IgG2a, kappa) |
specific for CD20; ref:rituximab | FACS, WB, IHC |
C20Mab-60 epitope-1 epitope-2 |
ongoing | BioLegnd |
CD39 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD39 mAb (C39Mab-1;rat IgG2a, kappa) |
specific for mouse CD39 | FACS, WB | C39Mab-1 | ○ | in preparation |
anti-CD39 mAb (C39Mab-2;rat IgG2a, lambda) |
specific for mouse CD39 | FACS | C39Mab-2 | ○ | in preparation |
CD44s | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44s mAb (C44Mab-5; mouse IgG1, kappa) |
Specific for CD44s (CD44 standard) | IHC, FACS, WB | C44Mab-5 epitope |
○ | abcam BioLegnd |
anti-CD44s mAb (C44Mab-46; mouse IgG1, kappa) |
specific for CD44s (CD44 standard) | FACS, IHC, WB | C44Mab-46 epitope-1 epitope-2 |
○ |
CD44s (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44s mAb (5-mG2a; mouse IgG2a) |
mouse IgG2a version of C44Mab-5; specific for CD44s (CD44 standard)。 | IHC, FACS, ADCC, CDC, antitumor activities | 5-mG2a | ○ |
CD44s (mouse IgG2a-f) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44s mAb (C44Mab-46-mG2a-f;mouse IgG2a) |
mouse IgG2a version of C44Mab-46 specific for CD44s (CD44 standard) |
IHC, FACS, WB, ADCC, CDC, antitumor activities | ○ |
CD44s | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44s mAb (C44Mab-1012; mouse IgM, kappa) |
Mab1 for CD44s (exon-6) | FACS | ○ | restricted | |
anti-CD44s mAb (C44Mab-1075; mouse IgG2a, kappa) |
Mab2 for CD44s (exon-6) | FACS | ○ | restricted | |
anti-CD44s mAb (C44Mab-1095; mouse IgG1, kappa) |
Mab3 for CD44s (exon-6) | FACS | restricted |
CD44v3 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44v3 mAb (C44Mab-6; mouse IgG1, kappa) |
specific for CD44v3 (oral cancer and colon cancer) |
FACS, WB, IHC, ELISA | IJMS | ○ | in preparation |
CD44v4 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v4 mAb (C44Mab-108; mouse IgG1, kappa) |
specific for CD44v4 (oral cancer) |
WB, IHC, ELISA | CIMB |
○ | in preparation |
CD44v5 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v5 mAb (C44Mab-3; mouse IgG1, kappa) |
specific for CD44v5 (pancreatic cancer) |
FACS, WB, IHC, ELISA | antibodies | ○ | in preparation |
CD44v6 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v6 mAb (C44Mab-9; mouse IgG1, kappa) |
specific for CD44v6 (colon cancer) |
FACS, WB, IHC, ELISA | IJMS | ○ | in preparation |
CD44v7 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v7/v8 mAb (C44Mab-34; mouse IgG1, kappa) |
specific for CD44v7/v8 (oral cancer) |
FACS, WB, IHC, ELISA | Biomedicines | ○ | |
CD44v8 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v8 mAb (C44Mab-94; mouse IgG1, kappa) |
specific for CD44v8 (gastric cancer) |
FACS, WB, IHC, ELISA | antibodies (submit) |
○ | |
CD44v9 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v9 mAb (C44Mab-1; mouse IgG1, kappa) |
specific for CD44v9 (colon cancer) |
FACS, WB, IHC, ELISA | CIMB | ○ | |
CD44v10 | Character | Application | Ref | Gene cloning | Company |
anti-CD44v10 mAb (C44Mab-18; mouse IgM, kappa) |
specific for CD44v10 (oral cancer) |
FACS, WB, IHC, ELISA | CIMB (submit) |
○ |
CD44v (mouse IgG1) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44v10 mAb (C44Mab-18-mG1; mouse IgG1, kappa) |
specific for CD44v10 | FACS, WB, IHC, ELISA | ongoing | ○ |
CD44v (mouse IgG2a-f) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44v3 mAb (C44Mab-6-mG2a-f;mouse IgG2a) |
IgG2a version of C44Mab-6 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v4 mAb (C44Mab-108-mG2a-f;mouse IgG2a) |
IgG2a version of C44Mab-108 | FACS, WB, IHC, ELISA | ongoing |
ongoing | |
anti-CD44v5 mAb (C44Mab-3-mG2a-f;mouse IgG2a) |
IgG2a version of C44Mab-3 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v6 mAb (C44Mab-9-mG2a-f;mouse IgG2a) |
IgG2a version of C44Mab-9 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v7/v8 mAb (C44Mab-34-mG2a-f;mouse IgG2a) |
mouse IgG2a version of C44Mab-34 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v8 mAb (C44Mab-94-mG2a-f;mouse IgG2a) |
mouse IgG2a version of C44Mab-94 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v9 mAb (C44Mab-1-mG2a-f;mouse IgG2a) |
mouse IgG2a version of C44Mab-1 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
anti-CD44v10 mAb (C44Mab-18-mG2a-f;mouse IgG2a) |
mouse IgG2a version of C44Mab-18 | FACS, WB, IHC, ELISA | ongoing | ongoing |
CD44v | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD44v3 mAb (C44Mab-1080; mouse IgG1, kappa) |
Mab6 for CD44v3 | FACS | restricted | ||
anti-CD44v3 mAb (C44Mab-1006; mouse IgG1, kappa) |
Mab11 for CD44v3 | FACS | ○ | restricted | |
anti-CD44v5 mAb (C44Mab-1088; mouse IgG1, kappa) |
Mab8 for CD44v5 | FACS | restricted | ||
anti-CD44v5 mAb (C44Mab-1003; mouse IgG1, kappa) |
Mab12 for CD44v5 | FACS | ○ | restricted | |
anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa) |
Mab7 for CD44v6 | FACS | restricted | ||
anti-CD44v6 mAb (C44Mab-1089; mouse IgG1, kappa) |
Mab9 for CD44v6 | FACS | restricted | ||
anti-CD44v6 mAb (C44Mab-1009; mouse IgG1, kappa) |
Mab13 for CD44v6 | FACS | ○ | restricted | |
anti-CD44v7 mAb (C44Mab-1030; mouse IgM, kappa) |
Mab4 for CD44v7 | FACS | restricted | ||
anti-CD44v7 mAb (C44Mab-1048; mouse IgG1, kappa) |
Mab5 for CD44v7 | FACS | restricted | ||
anti-CD44v7 mAb (C44Mab-1034; mouse IgG1, kappa) |
Mab10 for CD44v7 | FACS | ○ | restricted |
CD133 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD133 mAb (CMab-43;mouse IgG2a, kappa) |
specific for CD133 | FACS, WB, IHC, ADCC/CDC, antitumor activities | CMab-43 in vivo |
○ |
abcam BD |
CD271 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD271抗体 (G4B1;mouse IgG2a, kappa) |
cancer-specific mAb for CD271 | FACS, WB, IHC | anti-CD271 mAb | ○ | in preparation |
CD276 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-CD276 mAb | specific for CD276 |
EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EpCAM mAb (EpMab-16;mouse IgG2a, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-16 (1)
EpMab-16 (2) |
○ | merck |
anti-EpCAM mAb (EpMab-37;mouse IgG1, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-37 epitope |
○ | |
anti-EpCAM mAb (EpMab-3;mouse IgG1, kappa) |
specific for EpCAM | FACS | ○ |
EpCAM
(mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EpCAM mAb (EpMab-37-mG2a-f;mouse IgG2a) |
specific for EpCAM | FACS, WB, IHC, ADCC, CDC, antitumor activities |
EpMab-37 (1) EpMab-37 (2) |
○ | in preparation |
EpCAM | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-EpCAM mAb (EpMab-1123;mouse IgM, kappa) |
Mab1 for EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-1138;mouse IgM, kappa) |
Mab2 for EpCAM | FACS | |||
anti-EpCAM mAb (EpMab-1147;mouse IgG1, kappa) |
Mab3 for EpCAM | FACS | ○ | restricted in preparation |
|
anti-EpCAM mAb (EpMab-1007;mouse IgG1, kappa) |
Mab4 for EpCAM | FACS | ○ | restricted in preparation |
|
anti-EpCAM mAb (EpMab-1013;mouse IgG1, kappa) |
Mab5 for EpCAM | FACS | ○ | restricted | |
anti-EpCAM mAb (EpMab-1022;mouse IgG1, kappa) |
Mab6 for EpCAM | FACS | ○ | restricted | |
anti-EpCAM mAb (EpMab-1069;mouse IgG1, kappa) |
Mab7 for EpCAM | FACS | ○ | restricted |
TROP2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TROP2 mAb (TrMab-6;mouse IgG2b, kappa) |
specific for human TROP2; (ref:TNBC) | IHC, WB, FACS |
TrMab-6 MCF7 TNBC |
○ |
exbio |
anti-TROP2 mAb (TrMab-29;mouse IgG1, kappa) |
specific for human TROP2 | IHC, WB, FACS | TrMab-29 | ○ | merck |
TROP2 (humanized) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TROP2 mAb (Datopotamab;humanized IgG1, kappa) |
Humanized mAb for DS-1062/Dato-DXd (Daiichi-Sankyo) | FACS | ○ | ||
anti-TROP2 mAb (Sacituzumab;humanized IgG1, kappa) |
Humanized mAb (Sacituzumab govitecan;Trodelvy) | FACS | ○ |
TROP2 | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-TROP2 mAb (TrMab-1100;mouse IgG1, kappa) |
Mab1 for human TROP2 | FACS | ○ | restricted in preparation |
|
anti-TROP2 mAb (TrMab-1148;mouse IgG1, kappa) |
Mab3 for human TROP2 | FACS | ○ | restricted in preparation |
|
anti-TROP2 mAb (TrMab-1156;mouse IgG2b, kappa) |
Mab4 for human TROP2 | FACS | ○ | restricted in preparation |
HGF | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-HGF mAb (t8E4;mouse IgG1, kappa) |
specific for active HGF | WB, IHC |
SREP IJMS |
○ | Merck |
anti-HGF mAb (t5A11;mouse IgG1, kappa) |
specific for HGF | WB, IHC |
SREP IJMS |
○ | |
anti-HGF mAb (t1E4;mouse IgG2b, kappa) |
specific for HGF | neutralization |
SREP |
○ |
Podocalyxin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PODXL mAb (PcMab-47;mouse IgG1, kappa) |
specific for human PODXL | FACS, WB, IHC | PcMab-47 IHC_OSCC epitope |
○ | abcam exbio |
anti-PODXL mAb (PcMab-6;mouse IgG1, kappa) |
anti-PODXL CasMab | FACS | patent | ○ | |
anti-PODXL mAb (PcMab-60;mouse IgM, kappa) |
anti-PODXL CasMab | FACS | PcMab-60 epitope patent |
○ |
Podocalyxin (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PODXL mAb (47-mG2a;mouse IgG2a, kappa) |
IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a IHC_LK IHC_EC |
○ | |
anti-PODXL mAb (47-mG2a-f;mouse IgG2a, kappa) |
core fucose-deficient IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a-f | ○ | |
anti-PODXL mAb (PcMab-6-mG2a-f;mouse IgG2a) |
anti-PODXL CasMab; IgG2a version of PcMab-6 | FACS, ADCC・CDC | ○ | ||
anti-PODXL mAb (60-mG2a;mouse IgG2a, kappa) |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | 60-mG2a | ○ | |
anti-PODXL mAb (60-mG2a-f;mouse IgG2a, kappa) |
anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60 | FACS, ADCC/CDC, antitumor activities | 60-mG2a-f | ○ |
Podocalyxin (humanized) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-PODXL mAb (chPcMab-47;human IgG1) |
specific for human PODXL | FACS, WB, IHC | chPcMab-47 | ○ | |
anti-PODXL mAb (humPcMab-6;human IgG1) |
CasMab for PODXL; humanized mAb originated from PcMab-6 | FACS | ○ |
human podoplanin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hPDPN mAb(NZ-1; rat IgG2a) |
specific for human PDPN; the other clones: NZ-1.2( Sigma, Merck, MBL, Novus, Zenogen, Wako); NZ-1.3(Thermo), NC-08 (BioLegend) | IP、IHC, WB, FACS (Review; patent) |
NZ-1;
PIT NZ-1.2 CTC |
○ | Wako |
anti-hPDPN mAb (LpMab-2;mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
○ | |
anti-hPDPN mAb (LpMab-3;mouse IgG1, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS | LpMab-3 epitope Structure |
○ | MCP |
anti-hPDPN mAb (LpMab-7;mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | LpMab-7 OS epitope |
○ |
abcam MCP zenogen |
anti-hPDPN mAb (LpMab-9;mouse IgG1, kappa) | specific for human PDPN; epitope: Thr25 | WB, FACS | LpMab-9 epitope |
○ | MCP |
anti-hPDPN mAb (LpMab-10;mouse IgG3, kappa) | specific for human PDPN; epitope: PLAG1 Thr34 | IHC, WB, FACS | LpMab-10 | ○ | |
anti-hPDPN mAb (LpMab-12;mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG3 Thr52 | IHC, WB, FACS | LpMab-12 | ○ |
CST
Merck Hycult MCP zenogen |
anti-hPDPN mAb (LpMab-13;mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG2-3 | IHC, WB, FACS | LpMab-13 | ○ | Merck Hycult |
anti-hPDPN mAb (LpMab-16;mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | patent 2018-123699 | ○ | |
anti-hPDPN mAb (LpMab-17;mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS press release |
LpMab-17 | ○ |
BD Merck Hycult |
anti-hPDPN mAb (LpMab-19;mouse IgG2b, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC | LpMab-19 | ○ | Merck |
anti-hPDPN mAb (LpMab-21;mouse IgG2a, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC press release |
Cells2022 LpMab-21 in vivo |
○ |
Merck
BioLegend MCP |
anti-hPDPN mAb (LpMab-23;mouse IgG1, kappa) | CasMab | IHC, WB, FACS | LpMab-23 IHC patent |
○ |
BD exbio zenogen |
anti-hPDPN mAb (PMab-117;rat IgM, kappa) | CasMab | FACS | Cells2022 patent |
○ | zenogen |
human podoplanin (humanized) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-human PDPN mAb(NZ-8; human IgG1) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP、IHC, WB, FACS | NZ-8 | ○ | |
anti-human PDPN mAb(NZ-12; human IgG1) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP、IHC, WB, FACS | NZ-12 RIT |
○ | |
anti-human PDPN mAb(NZ-16; human IgG1) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP、IHC, WB, FACS | RIT | ○ | |
anti-human PDPN mAb(NZ-27; human IgG1) |
specific for human PDPN; humanized mAb originated from NZ-1 | IP、IHC, WB, FACS |
NZ-27 CAR-T |
○ | |
anti-human PDPN mAb(chLpMab-2; human IgG1) |
CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2 | IP、IHC, WB, FACS | chLpMab-2 | ○ | |
anti-human PDPN mAb(chLpMab-7;human IgG1) | specific for human PDPN; mouse-human chimeric mAb originated from LpMab-7 | IHC, WB, FACS | chLpMab-7 | ○ | |
anti-human PDPN mAb(chLpMab-23;human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23 | IHC, WB, FACS | chLpMab-23 | ○ | |
anti-human PDPN mAb(humLpMab-23;human IgG1) | CasMab for human PDPN; humanized mAb originated from LpMab-23 | IHC, WB, FACS | ○ |
mouse podoplanin | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti mouse PDPN mAb (PMab-1;rat IgG2a, kappa) |
specific for mouse PDPN --> anti-human PDPN |
IHC, WB, FACS | PMab-1 PMab-1_LEC epitope |
○ | abcam; MBL; Nov; Mer; BioL |
anti mouse PDPN mAb (mPMab-1;mouse IgG2a) | specific for mouse PDPN | IHC, WB, FACS |
mPMab-1 |
○ | |
rat PDPN | Character | Application | Ref | Gene cloning | Company |
anti-rat PDPN mAb (PMab-2;mouse IgG1, kappa) |
specific for rat PDPN | IHC, WB, FACS | PMab-2 PMab-2_epitope |
○ |
abcam Merck BioLegend |
rabbit PDPN | Character | Application | Ref | Gene cloning | Company |
anti-rabbit PDPN mAb (PMab-32;mouse IgG1, kappa) |
specific for rabbit PDPN | IHC, WB, FACS | PMab-32 epitope |
||
dog PDPN | Character | Application | Ref | Gene cloning | Company |
anti-dog PDPN mAb (PMab-38;mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
○ |
zenogen Wako |
anti-dog PDPN mAb (P38Bf;dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
○ | |
anti-dog PDPN mAb (PMab-48;mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
○ | zenogen |
bovine PDPN | Character | Application | Ref | Gene cloning | Company |
anti-bovPDPN mAb (PMab-44;mouse IgG1, kappa) | specific for bovine PDPN | IHC, WB, FACS | PMab-44;
epitope goat; sheep; alpaca |
○ | zenogen |
cat PDPN | Character | Application | Ref | Gene cloning | Company |
anti-cat PDPN mAb (PMab-52;mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
○ | zenogen |
tiger PDPN | Character | Application | Ref | Gene cloning | Company |
anti-tiger PDPN mAb (PMab-231;mouse IgG2a, kappa) |
specific for tiger PDPN | IHC, WB, FACS | PMab-231 epitope lion PDPN |
○ | zenogen |
horse PDPN | Character | Application | Ref | Gene cloning | Company |
anti-horse PDPN mAb (PMab-219;mouse IgG2a, kappa) |
specific for horse PDPN | WB, FACS, IHC | PMab-219 epitope PMab-219_epitope |
○ | zenogen |
anti-horse PDPN mAb (PMab-202;mouse IgG1, kappa) |
specific for horse PDPN | WB, FACS | PMab-202 epitope |
○ | zenogen |
pig PDPN | Character | Application | Ref | Gene cloning | Company |
anti-pig PDPN mAb (PMab-213;mouse IgG2b, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-213 epitope LEC |
○ | zenogen |
anti-pig PDPN mAb (PMab-210;mouse IgG1, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-210 epitope |
○ | zenogen |
goat PDPN | Character | Application | Ref | Gene cloning | Company |
anti-goat PDPN mAb (PMab-235;mouse IgG1, kappa) | specific for goat PDPN | IHC, WB, FACS | PMab-235 epitope |
○ | zenogen |
alpaca PDPN | Character | Application | Ref | Gene cloning | Company |
anti-aPDPN mAb (PMab-225;mouse IgG2b, kappa) | specific for alpaca PDPN | IHC, WB, FACS |
PMab-225 epitope |
○ | zenogen |
Tasmanian devil PDPN | Character | Application | Ref | Gene cloning | Company |
anti-TasPDPN PDPN (PMab-233;mouse IgG1, kappa) | specific for Tasmanian devil PDPN | IHC, WB, FACS | PMab-233br> epitope | ○ | zenogen |
bear PDPN | Character | Application | Ref | Gene cloning | Company |
anti-bear PDPN mAb (PMab-241;mouse IgG2b, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-241 epitope |
||
anti-bear PDPN mAb (PMab-247;mouse IgG1, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-247 IHC epitope |
○ | zenogen |
whale PDPN | Character | Application | Ref | Gene cloning | Company |
anti-whale PDPN mAb (PMab-237;mouse IgG1, kappa) |
specific for whale PDPN | IHC, WB, FACS | PMab-237 IHC epitope |
○ | zenogen |
sheep PDPN | Character | Application | Ref | Gene cloning | Company |
anti-sheep PDPN mAb (PMab-256;mouse IgG1, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-256 epitope |
○ | zenogen |
anti-sheep PDPN mAb (PMab-253;mouse IgM, kappa) |
specific for sheept PDPN | IHC, WB, FACS | PMab-253 | ○ | |
anti-sheep PDPN mAb (PMab-260;mouse IgM, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-260 | ○ | |
sea lion PDPN | Character | Application | Ref | Gene cloning | Company |
anti-seaPDPN mAb (PMab-269;mouse IgG1, kappa) | specific for sea lion PDPN | IHC, WB, FACS | PMab-269 epitope Steller Sea Lion |
○ | |
elephant PDPN | Character | Application | Ref | Gene cloning | Company |
anti-elePDPN mAb (PMab-265;mouse IgM, kappa) | specific for elephant PDPN | FACS | PMab-265 | ||
anti-elePDPN mAb (PMab-295;mouse IgG1, kappa) | specific for elephant PDPN | FACS, WB, IHC | PMab-295 epitope |
○ |
Ab.antibody |
ferret PDPN | Character | Application | Ref | Gene cloning | Company |
anti-ferret PDPN mAb (PMab-241;mouse IgG2b, kappa) |
anti-bear PDPN mAb crossreacts with ferret PDPN | IHC, WB, FACS | PMab-241 | ||
anti-ferret PDPN mAb (PMab-292;mouse IgG1, kappa) |
specific for ferret PDPN | IHC, WB, FACS | PMab-292 | ○ |
Ab.antibody |
hamster PDPN | Character | Application | Ref | Gene cloning | Company |
anti-hamPDPN mAb (PMab-281;mouse IgG3, kappa) | specific for hamster PDPN | FACS, IHC | PMab-281
epitope |
○ | |
anti-hamPDPN mAb (281-mG2a-f;mouse IgG2a, kappa) | specific for hamster PDPN; IgG2a version of PMab-281 | FACS, IHC |
PMab-281
epitope |
○ | |
giraffe PDPN | Character | Application | Ref | Gene cloning | Company |
anti-girPDPN mAb (PMab-301;mouse IgG1, kappa) | specific for giraffe PDPN | FACS, WB, IHC | |||
panda PDPN | Character | Application | Ref | Gene cloning | Company |
anti-panPDPN mAb () | specific for panda PDPN |
ATRX | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-ATRX mAb (AMab-6;mouse IgG1, kappa) |
specific for human ATRX | IHC, WB | AMab-6 AMab-6_epitope AMab-6_IHC |
abcam |
DGK | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-DGKalpha mAb (DaMab-2;mouse IgG1, kappa) |
specifi for DGKalpha | ICC | DaMab-2 epitope |
restricted | |
anti-DGKalpha mAb (DaMab-8;mouse IgG1, kappa) |
specific for DGKalpha | IHC | DaMab-8 |
○ | restricted |
anti-DGKgamma mAb (DgMab-6;mouse IgG1, kappa) |
specific for DGKgamma | ICC | DgMab-6 |
restricted | |
anti-DGKzeta mAb (DzMab-1;rat IgG2b, kappa) |
specific for DGKzeta | ICC |
DzMab-1 epitope |
restricted | |
anti-DGKeta mAb (DhMab-1;mouse IgG2a, kappa) |
specific for DGKeta | IHC | DhMab-1 | restricted | |
anti-DGKeata mAb (DhMab-4;mouse IgG2b, kappa) |
specific for DGKeta | IHC |
DhMab-4 ICC |
restricted | |
anti-DGKdelta mAb (DdMab-1;mouse IgG2a, kappa) |
specific for DGKdeta | IHC | DdMab-1 | restricted |
IDH | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-IDH1-R132H mAb (HMab-1; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-1 | ○ |
Merck
MBL; IBL; Sigma |
anti-IDH1-R132H mAb (HMab-2; mouse IgG1, kappa) | specific for IDH1-R132Hを | IHC, WB | HMab-2 | ○ | abcam |
anti-IDH1-R132S mAb (SMab-1; mouse IgG1, kappa) | specific for IDH1-R132S | IHC, WB | SMab-1 | ○ |
abcam
IBL; MBL Merck_Sigma |
anti-IDH1-R132G mAb (GMab-r1;rat IgG2a, kappa) | specific for IDH1-R132G | IHC, WB | GMab-r1 |
abcam MBL |
|
anti-IDH2-R172K mAb (KMab-1;rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB | KMab-1 | abcam MBL |
|
anti-IDH2-R172M mAb (MMab-1;rat IgG2b, kappa) | specific for IDH2-R172M | IHC, WB | MMab-1 |
abcam MBL |
|
anti-IDH2-R172W mAb (WMab-1;rat IgG2b, kappa) | specific for IDH2-R172W | IHC, WB | WMab-1 |
abcam MBL |
|
anti-IDH2-R172S mAb (SMab-2;mouse IgG1, kappa) | specific for IDH2-R172S | IHC, WB | SMab-2 | abcam | |
anti-IDH1 mAb (RMab-3;mouse IgG1, kappa) | specific for IDH1 | IHC, WB | RMab-3 |
BD MBL |
|
anti-IDH1 mAb (RcMab-1;rat IgG2a, kappa) | specific for IDH1 | IHC, WB | RcMab-1 |
abcam CST MBL |
|
anti-IDH2 mAb (RMab-22;mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | RMab-22 | MBL | |
anti-IDH2 mAb (KrMab-3;mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | KrMab-3 | CST BioLegend MBL |
|
anti-mIDH1/2 mAb (MsMab-1;mouse IgG1, kappa) | specific for mutated IDH1/2 | IHC, WB (IHCのref) |
TJEM Brain Tumor Pathol Cancer Med |
○ | abcam Merck |
anti-mIDH1/2 mAb (MsMab-2;rat IgG2a, kappa) | specific for mutated IDH1/2 | IHC, WB | MsMab-2 | ○ | MBL |
TERT | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-hTERT mAb (TpMab-1;mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-1 (press release) |
○ | |
anti-hTERT mAb (TpMab-2;mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA | ○ | ||
anti-hTERT mAb (TpMab-3;mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-3 (press release) |
○ | in preparation |
anti-hTERT mAb (TwMab-1;mouse IgG1, kappa) |
specific for hTERT | IHC, WB, ELISA | TwMab-1 | ○ | in preparation |
anti-hTERT mAb (TMab-6;mouse IgM, kappa) |
specific for hTERT | IHC |
TMab-6 TMab-6_epitope |
○ |
SARS-CoV-2 (S1 RBD) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 S1-RBD mAb (CvMab-1;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 319-338aa。 RBD:Receptor binding domain |
ELISA,WB, IHC | ○ | ||
anti- SARS-CoV-2 S1-RBD mAb (CvMab-2;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa |
ELISA, WB, IHC, neutralization | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-3;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 469-478aa。 |
ELISA,WB, IHC, neutralization | |||
anti SARS-CoV-2 S1-RBD mAb (CvMab-6;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, IHC, neutralization | CvMab-6 | ○ | |
anti-SARS-CoV-2 S1-RBD mAb (CvMab-7;mouse IgM, kappa) |
specific for SARS-CoV-2 S1-RBD epitope:459-478aa。 |
ELISA, WB, IHC, neutralization | ○ | ||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-13;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, IHC | ○ | ||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-17;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, neutralization, IHC | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-18;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, neutralization, IHC | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-24;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, IHC, neutralization | |||
anti-SARS-CoV-2 S1-RBD mAb (CvMab-25;mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, IHC, WB |
SARS-CoV-2 (S1 N terminus) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-32;mouse IgG2b, kappa) |
specific for SARS-CoV-2 S1N terminus | ELISA, IHC, WB |
SARS-CoV-2 (S2) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-36;mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA, WB | |||
anti-SARS-CoV-2 mAb (CvMab-62;mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA | ○ |
SARS-CoV-2 (bi-specific) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-SARS-CoV-2 mAb (CvMab-bis1) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-H_CvM62scFv |
○ | |||
anti-SARS-CoV-2 mAb (CvMab-bis2) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-L_CvM62scFv |
○ | |||
anti-SARS-CoV-2 mAb (CvMab-bis3) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-62-H_CvM6scFv |
○ | |||
anti-SARS-CoV-2 mAb (CvMab-bis4) |
specific for SARS-CoV-2 S1+S2
bispecific mAb CvMab-62-L_CvM6scFv |
○ |
SARS-CoV-2 (humanized) | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
Bebtelovimab (human IgG1, lambda) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; weak activity for all variants | ○ | ||
Cilgavimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Cilgavimab plus tixagevimab (EVUSHELD) |
Neutralization; weak activity for BA.2; resistant for BA.4/5 | ○ | ||
Casirivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Casirivimab plus imdevimab (Ronapreve) |
Neutralization; weak activity for Omicron | ○ | ||
Bamlanivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; no activity for Omicron | ○ | ||
Bebtelovimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | ○ | |||
Cilgavimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | ○ | |||
CvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | ○ | |||
CvMab-62-H_Cilgavimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | ○ |
RdRP | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-RdRP mAb (RdMab-2;mouse IgG2a, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB, IP, ICC | RdMab-2 | ||
anti-RdRP mAb (RdMab-13;mouse IgM, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB | RdMab-13 | ||
anti-RdRP mAb (RdMab-15;mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-15 | ||
anti-RdRP mAb (RdMab-16;mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-16 | ||
anti-RdRP mAb (RdMab-20;mouse IgG2b, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB | RdMab-20 |
dog PDPN | Character | Application | Ref | Gene cloning | Company |
---|---|---|---|---|---|
anti-dog PDPN mAb (P38Bf;dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
○ | |
dog EGFR | Character | Application | Ref | Gene cloning | Company |
anti-EGFR mAb (134-mG2a-f;mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR Osteosarcoma Fibroblastic Mammary |
○ | |
anti-EGFR mAb (E134Bf;canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
○ | |
dog HER2 | Character | Application | Ref | Gene cloning | Company |
anti-HER2 mAb (H77Bf;canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
○ | |
anti-HER2 mAb (H2Mab-41;mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
○ | |
EGFR-HER2 (bispecific) | Character | Application | Ref | Gene cloning | Company |
anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | ○ | |
dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
anti-dog PD-L1 mAb (L1Mab-347;mouse IgG1, kappa) |
specific for dog PD-L1 | FACS, IHC | ○ | ||
anti-dog PD-L1 mAb (L1Mab-348; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-349; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-350; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-351; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
anti-dog PD-L1 mAb (L1Mab-353; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
anti-dog PD-L1 mAb (L1Mab-355; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
anti-dog PD-L1 mAb (L1Mab-356; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA |